NZ599558A - Dosing regimen associated with long-acting injectable paliperidone esters - Google Patents

Dosing regimen associated with long-acting injectable paliperidone esters

Info

Publication number
NZ599558A
NZ599558A NZ599558A NZ59955810A NZ599558A NZ 599558 A NZ599558 A NZ 599558A NZ 599558 A NZ599558 A NZ 599558A NZ 59955810 A NZ59955810 A NZ 59955810A NZ 599558 A NZ599558 A NZ 599558A
Authority
NZ
New Zealand
Prior art keywords
injectable
patient
paliperidone palmitate
day
injectable paliperidone
Prior art date
Application number
NZ599558A
Other languages
English (en)
Inventor
Cristiana Gassmann-Mayer
David W Hough
Bart M M Remmerie
Peter H Lewyn-Briscoe
Srihari Gopal
Mahesh N Samtani
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43302985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ599558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NZ599558A publication Critical patent/NZ599558A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ599558A 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters NZ599558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
PCT/US2010/054807 WO2011053829A1 (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
NZ599558A true NZ599558A (en) 2014-09-26

Family

ID=43302985

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599558A NZ599558A (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Country Status (12)

Country Link
US (2) US20110105536A1 (https=)
EP (1) EP2493473A1 (https=)
JP (2) JP2013509435A (https=)
KR (1) KR20120116401A (https=)
CN (1) CN102802631A (https=)
AU (2) AU2010313290A1 (https=)
BR (1) BR112012010195A2 (https=)
CA (1) CA2742393A1 (https=)
CL (1) CL2012001110A1 (https=)
MX (1) MX2012005083A (https=)
NZ (1) NZ599558A (https=)
WO (1) WO2011053829A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR102318070B1 (ko) 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
HUE065359T2 (hu) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Szorbitán-észtereket tartalmazó gyógyászati készítmények
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
ES2765036T3 (es) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden esteres de ácidos grasos
ES2950418T3 (es) * 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden alcohol bencílico
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
BR112016021535A8 (pt) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
RS65024B1 (sr) * 2015-04-07 2024-01-31 Janssen Pharmaceutica Nv Dozni režim za propuštene doze injektibilnih estara paliperidona sa produženim delovanjem
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
AU2020356529A1 (en) 2019-09-25 2022-05-19 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
TW202210119A (zh) * 2020-09-02 2022-03-16 比利時商健生藥品公司 具有最佳化止擋件布置之預充填注射器
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
ES2981035T3 (es) * 2020-11-30 2024-10-07 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada
KR102794804B1 (ko) * 2020-11-30 2025-04-10 얀센 파마슈티카 엔브이 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
JP2024511353A (ja) * 2021-03-17 2024-03-13 メドインセルル エス．エー． リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
WO2006114384A1 (en) 2005-04-25 2006-11-02 Janssen Pharmaceutica N.V. Preparation of aseptic 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4h-pyridio[1,2-a]pyrimidin-4-one palmitate ester
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP1940834A2 (en) * 2006-08-14 2008-07-09 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone)
KR102318070B1 (ko) * 2007-12-19 2021-10-27 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법

Also Published As

Publication number Publication date
AU2010313290A1 (en) 2012-05-17
AU2015243103A1 (en) 2015-11-05
WO2011053829A1 (en) 2011-05-05
US20110105536A1 (en) 2011-05-05
JP2016102123A (ja) 2016-06-02
CL2012001110A1 (es) 2012-10-19
MX2012005083A (es) 2012-09-28
CN102802631A (zh) 2012-11-28
EP2493473A1 (en) 2012-09-05
JP2013509435A (ja) 2013-03-14
US20130331402A1 (en) 2013-12-12
BR112012010195A2 (pt) 2016-04-26
KR20120116401A (ko) 2012-10-22
CA2742393A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
NZ599558A (en) Dosing regimen associated with long-acting injectable paliperidone esters
NZ586221A (en) Dosing regimen associated with long acting injectable paliperidone esters
JP2013509435A5 (https=)
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
IL309340A (en) Dosing regimen for missing doses of paliperidone long-acting injectable esters
NZ732507A (en) Improved compositions for treating muscular dystrophy
MX2022008236A (es) Metodos para administrar altas concentraciones de oxido nitrico.
JP2012193216A5 (https=)
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
RU2015127794A (ru) Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
RU2613324C3 (ru) Композиция для контролируемой стимуляции яичников
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
JP2018510894A5 (https=)
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
EP3970729A3 (en) Methods of administering high concentrations of nitric oxide
MX2013003523A (es) Composicion farmaceutica de dosis baja.
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
JP2014530246A5 (https=)
SI2686002T1 (en) A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen
NZ590489A (en) Unit dosage of apadenoson
EA032959B1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции

Legal Events

Date Code Title Description
AABA Application abandoned
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 29 OCT 2017 BY AJ PARK

Effective date: 20150505

LAPS Patent lapsed